Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultevursen versus sham in USH2A exon 13 retinitis pigmentosa
NL-OMON60894Phase 2Active, not recruiting
- Sponsor
- Laboratoires Théa
- Start
- Oct 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) and Usher syndrome type 2A (USH2A) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Annualized percent change from baseline in ellipsoid zone width. Started Oct 2025; status: active, not recruiting.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2A (USH2A)
Beyond the preview
Go deeper on NL-OMON60894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60894.